Mammana R B, Levitsky S, Beckman C B, Vasu A, Sernaque D
Ann Thorac Surg. 1981 Apr;31(4):347-9. doi: 10.1016/s0003-4975(10)60963-0.
The purpose of this study was to investigate the changes in serum and urine potassium before, during, and after the administration of potassium cardioplegia using a solution containing 28 mEq/L of potassium chloride in 20 consecutive patients with acquired heart disease. The data obtained suggest that the concentration of potassium administered does not result in inordinately elevated serum potassium levels (peak, 4.6 +/- 0.18 mEq/L at 2 hours of multidose hypothermic potassium cardioplegia) during or after infusion. Additionally, the urinary excretion of potassium increased during infusion and eventually exceeded the amount of potassium infused. While hypothermic potassium cardioplegia appears to be a safe and efficient method of myocardial protection, continued surveillance of postoperative potassium levels remains necessary to detect obligatory urinary potassium excretion following cardiopulmonary bypass and operation.
本研究的目的是调查20例连续性获得性心脏病患者在使用含28 mEq/L氯化钾溶液进行钾停搏液给药前、给药期间及给药后的血清和尿钾变化。获得的数据表明，给药的钾浓度在输注期间或输注后不会导致血清钾水平过度升高（在多剂量低温钾停搏液输注2小时时，峰值为4.6±0.18 mEq/L）。此外，输注期间尿钾排泄增加，最终超过输注的钾量。虽然低温钾停搏液似乎是一种安全有效的心肌保护方法，但仍有必要持续监测术后钾水平，以检测体外循环和手术后必然出现的尿钾排泄情况。
